OA12097A - 2,4-Diaminopyrimidine compounds useful as immunosuppressants. - Google Patents

2,4-Diaminopyrimidine compounds useful as immunosuppressants. Download PDF

Info

Publication number
OA12097A
OA12097A OA1200200156A OA1200200156A OA12097A OA 12097 A OA12097 A OA 12097A OA 1200200156 A OA1200200156 A OA 1200200156A OA 1200200156 A OA1200200156 A OA 1200200156A OA 12097 A OA12097 A OA 12097A
Authority
OA
OAPI
Prior art keywords
alkyl
dihydro
aryl
heteroaryl
composition according
Prior art date
Application number
OA1200200156A
Other languages
English (en)
Inventor
Todd Andrew Blumenkopf
Eileen Elliott Mueller
Eric Jan Roskamp
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA12097A publication Critical patent/OA12097A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (16)

12097 Λ -55- 7,8-Dihydro-6H-pynmido[5,4-b}[1,4]thiazine; 3,4-Dihydro-2H-1-thia-4,5,8-tnaza-naphthaiene;6,7-Dihydro-5H-8-thia-1,2,4,5-tetraaza-naohthaiene; 7,8-Dihydro-6H-5-thia-1.2,4,8-tetraaza-naphthalene; 7,8-Dihydro-5H-5-thia-1,2,3,8-tetraaza-naphthaiene; 6,7-Dihydfo-5H-8-thia- 1,2,3,5-tetraaza-naphthaiene; 5,6,7,8-Tetra'nydro-pyrido[3,2-d]pyrimidine; 1,2,3,4-Tetrahydro-pyndo[2,3~d]pyridazine, 5,6,7,8-Tetrahydro-pyrido[2,3-bjpyrazine; 5,6,7,8-Tetrahydro-pyrido[3,2-e][1,2,4]triazine, 5,6,7,8-Tetrahydro-pyrido{2,3-eJ[1,2,4]triazine; 5,6,7,8-Tsirahydro-pyrido[3,2-d][1,2,3]triazine; and 5,6,7,8-Tetrahydro-pyrido[2,3-d][1,2,3}triazine.
15. A pharmaceutical composition comprising an effective amount of acompouna according to ciaim 1, and a pharmaceutical carrier. 16 A pharmaceutical composition according to ciaim 15, for treatment orprévention of a condition in a mammai wherein therapeutic benefit is achieved by modulationof a T-cel! mediated ceiiuiar process. 17 A pharmaceutical composition according to ciaim 15, for treatment orprévention of transpiant rejection in a mammai
18. A pnarmaceutica! composition according to ciaim 15, for treatment orprévention of autoimmune disease in a mammai.
19. A pharmaceutical composition according to ciaim 15, for treatment orprévention of infiammatory disease in a mammai.
20. A pharmaceutical composition according to ciaim 15, for treatment orprévention of aiiergy in a mammai
21. A pharmaceutica! composition according to ciaim 15, for treating 7-ceüieukemia or T-ceil iymphoma in a mammai. 22 A pharmaceutical composition according fc ciaim 15, for the treatment of adisease in a mammai wherein treatment can be effected by inhibiting activation of T-ceils, orthe results of said activation.
23. A pharmaceutical composition according to ciaim 15, further comprising anadditions! agent which modulâtes the mammaiian immune System or wnich is an arsti-inflammatory agent.
24. A pharmaceutical composition according to ciaim 15, usefui in the treatmentof a disorder or condition in a mammai seiected from the aroup consistina of ssthma, haylever, hives, infantile eczema, atopie dermatitis, and other allergie diseases invoivingantibody-mediated (intermediate-type) hvpersensitivity réactions, transpiant rejection,psoriasis, uteerative coiitis, Crohn's disease, iupus, multiple scierosis, rheurnatoid arthritis,type I diabètes, autoimmune thyroid disorders, T-cel! maiignancies mciuding T-ce!1 ieukemiaand T-cel! iymphoma, and Aizhetmer’s disease
25. A pharmaceutical composition according to ciaim 15, usefui to inhibiî tyrosinekinase Lck in a mammai. -56- 1 2097 26 A pharmaceutical composition according to ciasm 16, whersîn said ccmpcunclis proviasd as a pharmacsutically acceptable sait, solvaie or hycrate thereci.
27. Use of a composition of claim 15 in the manufacture of a substance foruse in a method of inhibiting protein tyrosine kinase Lck in a mammal.
28. The use of claim 27 wherein one or more additional agents thatmodulate a mammalian immune response or which are anti-inflammatory agents areused separately or in combination with said composition.
29. Use of a composition according to claim 15 effective in treating orpreventing a disorder or condition selected from asthma, hay fever, hives, infantileeczema, atopie dermatitis, and other allergie diseases involving antibody-mediated(intermediate-type) hypersensitivity reactions, transplant rejection, psoriasis,ulcerative colitis, Crohn’s disease, lupus, multiple sclerosis, rheumatoid arthritis, type1 diabètes, autoimmune thyroid disorders, T-cell malignancies including T-cellleukemia and T-cell lymphoma, and Alzheimer’s disease in the manufacture of amédicament for use in a said method.
30. Use of a pharmaceutical composition according to claim 15, in themanufacture of a médicament for use in a method for treating or preventing transplantrejection in a mammal.
31. Use of a pharmaceutical composition according to claim 15, in themanufacture of a médicament for use in a method for treating or preventingautoimmune disease in a mammal.
32. Use of a pharmaceutical composition according to claim 15, in themanufacture of a médicament for use in a method for treating or preventinginflammatory disease in a mammal.
33. Use of a pharmaceutical composition according to claim 15, in themanufacture of a médicament for use in a method for treating or preventing allergiedisease in a mammal.
OA1200200156A 1999-11-30 2000-11-09 2,4-Diaminopyrimidine compounds useful as immunosuppressants. OA12097A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16822499P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
OA12097A true OA12097A (en) 2006-05-04

Family

ID=22610621

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200156A OA12097A (en) 1999-11-30 2000-11-09 2,4-Diaminopyrimidine compounds useful as immunosuppressants.

Country Status (33)

Country Link
EP (1) EP1242403B1 (fr)
JP (1) JP3955468B2 (fr)
KR (1) KR20020059826A (fr)
CN (1) CN1402720A (fr)
AP (1) AP2002002530A0 (fr)
AT (1) ATE315036T1 (fr)
AU (1) AU1047601A (fr)
BG (1) BG106695A (fr)
BR (1) BR0015995A (fr)
CA (1) CA2392971C (fr)
CO (1) CO5261519A1 (fr)
CZ (1) CZ20021703A3 (fr)
DE (1) DE60025385T2 (fr)
EA (1) EA200200411A1 (fr)
EE (1) EE200200275A (fr)
ES (1) ES2253266T3 (fr)
GT (1) GT200000200A (fr)
HN (1) HN2000000264A (fr)
HU (1) HUP0203300A3 (fr)
IL (1) IL149103A0 (fr)
IS (1) IS6339A (fr)
MA (1) MA26846A1 (fr)
MX (1) MXPA02005350A (fr)
NO (1) NO20022557L (fr)
OA (1) OA12097A (fr)
PA (1) PA8506801A1 (fr)
PE (1) PE20010900A1 (fr)
PL (1) PL355946A1 (fr)
SV (1) SV2002000231A (fr)
TN (1) TNSN00232A1 (fr)
TR (1) TR200201431T2 (fr)
UY (1) UY26455A1 (fr)
WO (1) WO2001040215A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02007957A (es) * 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
SK2002003A3 (en) * 2000-08-31 2004-04-06 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
WO2003030909A1 (fr) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
DE60308387T2 (de) 2002-08-02 2007-09-20 Vertex Pharmaceuticals Inc., Cambridge Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
AU2005205167A1 (en) * 2004-01-16 2005-07-28 Novartis Ag 2, 4 - diaminopyrimidines and their use for inducing cardiomyogenesis
KR20070085340A (ko) * 2004-10-12 2007-08-27 디코드 제네틱스, 아이엔씨. 폐쇄성 동맥 질환용의 아릴 설폰아미드 주변 치환된바이사이클릭 화합물
US20060161001A1 (en) * 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
TW200734327A (en) 2005-11-03 2007-09-16 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
CA2652648C (fr) 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines servant d'inhibiteurs des proteines kinases
CN101563336A (zh) * 2006-03-16 2009-10-21 诺瓦提斯公司 用于治疗特别是黑素瘤的杂环有机化合物
KR20100017766A (ko) 2007-05-10 2010-02-16 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤조-1,4-디아제핀 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 이의 용도
BRPI0818338A2 (pt) * 2007-10-16 2015-04-22 Daiichi Sankyo Co Ltd Composto de pirimidil indolina
KR20120094920A (ko) 2009-09-25 2012-08-27 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
KR20120096474A (ko) 2009-09-25 2012-08-30 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
KR101708761B1 (ko) * 2012-04-13 2017-02-21 주식회사 머쉬메드 퓨린 유도체 또는 그의 염을 포함하는 아토피성 피부염의 예방 또는 치료용 조성물
WO2015054317A1 (fr) 2013-10-07 2015-04-16 Kadmon Corporation, Llc Inhibiteurs de la rho kinase
KR102563325B1 (ko) * 2017-06-30 2023-08-03 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
WO2019000683A1 (fr) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Inhibiteur de protéine kinase associée à rho, composition pharmaceutique contenant celui-ci, son procédé de préparation et ses applications
WO2019001572A1 (fr) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Inhibiteur de protéine kinase associée à rho, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0837063A1 (fr) * 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
HUP0203300A3 (en) 2003-10-28
NO20022557D0 (no) 2002-05-29
HN2000000264A (es) 2001-05-21
CN1402720A (zh) 2003-03-12
EE200200275A (et) 2003-10-15
PA8506801A1 (es) 2002-04-25
TR200201431T2 (tr) 2002-09-23
UY26455A1 (es) 2001-07-31
EP1242403B1 (fr) 2006-01-04
CA2392971C (fr) 2008-10-07
PE20010900A1 (es) 2001-09-08
BG106695A (bg) 2002-12-29
AP2002002530A0 (en) 2002-06-30
JP3955468B2 (ja) 2007-08-08
CA2392971A1 (fr) 2001-06-07
DE60025385T2 (de) 2006-08-24
GT200000200A (es) 2002-05-23
MXPA02005350A (es) 2002-12-11
ATE315036T1 (de) 2006-02-15
WO2001040215A1 (fr) 2001-06-07
DE60025385D1 (de) 2006-03-30
MA26846A1 (fr) 2004-12-20
IL149103A0 (en) 2002-11-10
EP1242403A1 (fr) 2002-09-25
NO20022557L (no) 2002-05-29
KR20020059826A (ko) 2002-07-13
PL355946A1 (en) 2004-05-31
TNSN00232A1 (fr) 2005-11-10
EA200200411A1 (ru) 2002-10-31
HUP0203300A2 (hu) 2003-02-28
BR0015995A (pt) 2002-08-06
ES2253266T3 (es) 2006-06-01
CO5261519A1 (es) 2003-03-31
AU1047601A (en) 2001-06-12
JP2003515602A (ja) 2003-05-07
IS6339A (is) 2002-04-12
SV2002000231A (es) 2002-07-16
CZ20021703A3 (cs) 2003-06-18

Similar Documents

Publication Publication Date Title
CA2392971C (fr) Composes de 2,4-diaminopyrimidine utilises comme immunodepresseurs
US7101869B2 (en) 2,4-diaminopyrimidine compounds useful as immunosuppressants
TWI699359B (zh) ４ｈ-吡咯［３,２-ｃ］吡啶-４-酮衍生物
KR102534962B1 (ko) 8,9-디하이드로이미다졸[1,2-a]피리미도[5,4-e]피리미딘-5(6H)-케톤계 화합물
KR102085121B1 (ko) 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도
JP5487214B2 (ja) キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
TWI534145B (zh) 四氫吡啶并嘧啶衍生物
CA2947002C (fr) Composes de pyrazole et leur utilisation en tant que bloqueurs des canaux calciques de type t
AU2019246753A1 (en) Novel compounds and compositions for inhibition of FASN
TW202106670A (zh) 用於治療癌症之醯基磺醯胺
TW200940544A (en) Inhibitors of PI3 kinase
RS61141B1 (sr) Inhibitori diacilglicerol aciltransferaze 2
TW201008929A (en) Organic compounds as Smo inhibitors
IL287390B2 (en) 4h-pyrrolo[3,2-c]pyridin-4-one compounds
TW201113267A (en) Quinazolines as potassium ion channel inhibitors
EA017392B1 (ru) Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ
US20230416249A1 (en) N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer
US20200216439A1 (en) Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones
WO2014026467A1 (fr) Composés de pyrimidine substitués bicycliques